Lexaria Bioscience

LEXX

Market cap $23.3M

Overview Fund Activity

1.19 USD

+0.12

11.21%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.19

0.00

0%

1 day

11.21%

5 days

16.67%

1 month

42.77%

3 months

16.67%

6 months

-17.36%

Year to date

-48.26%

1 year

-66.19%

5 years

-73.44%

10 years

-73.44%

About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Employees: 7

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

6.02% more ownership

Funds ownership: 7.06% [Q1] → 13.08% (+6.02%) [Q2]

5% less funds holding

Funds holding: 22 [Q1] → 21 (-1) [Q2]

6% less capital invested

Capital invested by funds: $2.12M [Q1] → $2M (-$118K) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

236% upside

Avg. target

$4

236% upside

High target

$4

236% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

$4

Buy

Maintained

29 Jul 2025

See Analyst Rankings

Financial journalist opinion

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Kelowna, British Columbia – August 27, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, today announced that it will participate in the 27 th Annual H.C. Wainwright Global Investment Conference, taking place September 8 th through September 10 th , 2025. Richard Christopher, Chief Executive Officer of Lexaria Bioscience, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. His presentation will be available for remote viewing anytime after 7:00 AM EST on September 5 th at this provided link .

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study"). "We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study," said John Docherty, Lexaria's President and CSO.

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Kelowna, British Columbia – TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization (“ CRO ”) has completed the important study milestone known as last patent last visit (“ LPLV ”) in Lexaria's Phase 1b glucagon-like peptide-1 (“ GLP-1 ”) study in Australia, GLP-1-H24-4 (the “ Study ”). “We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study,” said John Docherty, Lexaria's President and CSO. “Study work continues with full sample and data analyses currently underway in order to reach our late 2025 final reporting objective.”

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. The market for obesity and diabetes control drugs such as GLP-1 is growing at faster rates than nearly anyone originally anticipated, with revenues now expected to exceed $150 billion by 2030.

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and 5 relative to the Rybelsus® control study arm 4. "We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria.

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide KELOWNA, BC / ACCESS Newswire / July 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update as the industry continues to outperform earlier revenue growth projections. Global pharmaceutical corporations are competing desperately to secure either a foothold, or dominance, in what is currently the fastest growing pharmaceutical sector in the world: GLP-1 weight loss and diabetes control.

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

See News Rankings

Charts implemented using Lightweight Charts™